RHOA and neurodegenerative disease: Since increased RhoA activity has been noted in previous in vivo TBI models [30], and more recently inhibition of ROCK, a downstream effector of RhoA, has been shown to be an important therapeutic target in various neurodegenerative disease [31], we asked whether integrin-activated Rho-ROCK signaling may contribute to neuronal injury in our model.